The FDA recently approved the first biosimilar for patients with certain breast or stomach cancers. Marketed as Ogivri, trastuzumab-dkst is the second biosimilar approved in the United States to treat cancer.
Trastuzumab-dkst is biosimilar to trastuzumab, a monoclonal antibody that was approved in 1998 and is sold under the brand name Herceptin. The newly approved biosimilar is indicated for patients with breast or metastatic stomach tumors that are ERBB2 (formerly human epidermal growth factor receptor 2 [HER2] or HER2/neu) positive.
Voelker R. Second Cancer Biosimilar Approved. JAMA. 2018;319(3):220. doi:10.1001/jama.2017.20642
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: